ES2720779T3 - Preparación de muestras lipémicas de plasma o de suero para el establecimiento de una interferencia de lípidos - Google Patents
Preparación de muestras lipémicas de plasma o de suero para el establecimiento de una interferencia de lípidos Download PDFInfo
- Publication number
- ES2720779T3 ES2720779T3 ES16187839T ES16187839T ES2720779T3 ES 2720779 T3 ES2720779 T3 ES 2720779T3 ES 16187839 T ES16187839 T ES 16187839T ES 16187839 T ES16187839 T ES 16187839T ES 2720779 T3 ES2720779 T3 ES 2720779T3
- Authority
- ES
- Spain
- Prior art keywords
- plasma
- sample
- lipemic
- serum
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 114
- 230000001000 lipidemic effect Effects 0.000 title claims abstract description 90
- 210000002966 serum Anatomy 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 60
- 230000036961 partial effect Effects 0.000 claims abstract description 28
- 239000006228 supernatant Substances 0.000 claims abstract description 26
- 238000005119 centrifugation Methods 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims description 89
- 239000012491 analyte Substances 0.000 claims description 53
- 230000000694 effects Effects 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 24
- 238000005259 measurement Methods 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 19
- 238000011895 specific detection Methods 0.000 claims description 17
- 239000007858 starting material Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 84
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 30
- 239000012071 phase Substances 0.000 description 20
- 101800004937 Protein C Proteins 0.000 description 13
- 102000017975 Protein C Human genes 0.000 description 13
- 101800001700 Saposin-D Proteins 0.000 description 13
- 229960000856 protein c Drugs 0.000 description 13
- 230000015271 coagulation Effects 0.000 description 9
- 238000005345 coagulation Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010998 test method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical class CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16187839.2A EP3293521B1 (de) | 2016-09-08 | 2016-09-08 | Herstellung lipämischer plasma- oder serumproben für die bestimmung einer lipidinterferenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2720779T3 true ES2720779T3 (es) | 2019-07-24 |
Family
ID=56936286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16187839T Active ES2720779T3 (es) | 2016-09-08 | 2016-09-08 | Preparación de muestras lipémicas de plasma o de suero para el establecimiento de una interferencia de lípidos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10488308B2 (OSRAM) |
| EP (1) | EP3293521B1 (OSRAM) |
| JP (1) | JP7022538B2 (OSRAM) |
| CN (1) | CN107807024B (OSRAM) |
| CA (1) | CA2978476C (OSRAM) |
| ES (1) | ES2720779T3 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113196064B (zh) * | 2019-01-29 | 2022-09-27 | 美国西门子医学诊断股份有限公司 | 降低血红蛋白A1c测定中的英脱利匹特/脂血干扰的浊度归一化算法和方法 |
| CN111929449A (zh) * | 2020-08-28 | 2020-11-13 | 保定天岳生物工程有限公司 | 一种aptt检测试剂盒 |
| EP4209234B1 (en) * | 2022-01-11 | 2026-03-25 | Fenwal, Inc. | Adjustment of target interface position in a centrifuge based on lipid concentration |
| CN116907961A (zh) * | 2023-06-27 | 2023-10-20 | 郴州市第一人民医院 | 一种消减脂血标本血脂干扰的方法 |
| CN119901692B (zh) * | 2023-10-28 | 2025-12-02 | 柏荣诊断产品（上海）有限公司 | 一种减弱脂血对透散射融合增强免疫比浊检测影响的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4977685A (OSRAM) * | 1972-11-29 | 1974-07-26 | ||
| DE4223355A1 (de) * | 1992-07-16 | 1994-01-20 | Boehringer Mannheim Gmbh | Verfahren und Reagenz zur spezifischen Bestimmung von LDL in Serumproben |
| JP4273311B2 (ja) | 2002-04-26 | 2009-06-03 | 株式会社シノテスト | 試料中の測定対象物質の測定方法及び測定試薬 |
| CN101398422B (zh) * | 2008-10-28 | 2012-09-05 | 四川大学华西医院 | 高甘油三脂对血红蛋白浓度测定干扰的消除方法 |
| US20130084592A1 (en) | 2011-10-04 | 2013-04-04 | Siemens Healthcare Diagnostics Inc. | Methods for correcting assay measurements |
-
2016
- 2016-09-08 ES ES16187839T patent/ES2720779T3/es active Active
- 2016-09-08 EP EP16187839.2A patent/EP3293521B1/de active Active
-
2017
- 2017-09-05 CN CN201710789597.6A patent/CN107807024B/zh active Active
- 2017-09-06 CA CA2978476A patent/CA2978476C/en active Active
- 2017-09-07 JP JP2017171651A patent/JP7022538B2/ja active Active
- 2017-09-07 US US15/698,618 patent/US10488308B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107807024A (zh) | 2018-03-16 |
| EP3293521A1 (de) | 2018-03-14 |
| CN107807024B (zh) | 2021-11-23 |
| US10488308B2 (en) | 2019-11-26 |
| CA2978476A1 (en) | 2018-03-08 |
| EP3293521B1 (de) | 2019-01-02 |
| CA2978476C (en) | 2024-06-18 |
| JP2018040799A (ja) | 2018-03-15 |
| US20180067022A1 (en) | 2018-03-08 |
| JP7022538B2 (ja) | 2022-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107807024B (zh) | 制备用于确定脂质干扰的脂血血浆或血清样本 | |
| Nikolac | Lipemia: causes, interference mechanisms, detection and management | |
| Lima-Oliveira et al. | Sample management for clinical biochemistry assays: Are serum and plasma interchangeable specimens? | |
| Saracevic et al. | The evaluation and comparison of consecutive high speed centrifugation and LipoClear® reagent for lipemia removal | |
| Guder et al. | The Haemolytic, Icteric and Lipemic Sample-Recommendations Regarding their Recognition and Prevention of Clinically Relevant Interferences | |
| CN103149370B (zh) | 脂蛋白(a)检测试剂盒 | |
| CN103063848A (zh) | 一种用免疫比浊法测定载脂蛋白c2的试剂盒 | |
| US20220113322A1 (en) | Rapid measurement of total vitamin d in blood | |
| CN106290907B (zh) | 全血中血清淀粉样蛋白a定量检测试剂以及检测方法 | |
| Yano et al. | Comparison of two homogeneous LDL-cholesterol assays using fresh hypertriglyceridemic serum and quantitative ultracentrifugation fractions | |
| ES2857551T3 (es) | Calibración de anticoagulante lúpico | |
| Kazmierczak | Interferences of hemolysis, lipemia and high bilirubin on laboratory tests | |
| CN108008135B (zh) | 一种载脂蛋白b测定试剂盒 | |
| US20130224777A1 (en) | Screening method for finding samples having antiphospholipid antibodies | |
| JP6028314B2 (ja) | ループスアンチコアグラントの検出方法 | |
| CN105548573A (zh) | 检测kappa轻链含量的试剂盒、方法及用途 | |
| CN106546729B (zh) | 一种去除干式免疫荧光定量法检测中血清基质效应的新工艺方法 | |
| CN106645749B (zh) | 溶血剂及应用 | |
| KR20220082858A (ko) | 응고 검정 장치 및 이의 방법 | |
| Fernández-Pardo et al. | Screening for hyperglycerolemia by triglyceride assay in urine | |
| JP2004069697A (ja) | ループスアンチコアグラント検出試薬キット | |
| CN107860930A (zh) | 一种心型脂肪酸结合蛋白的免疫比浊检测试剂和方法 | |
| JP4163056B2 (ja) | 血中インスリン濃度測定用添加剤組成物及びそれを含む採血管 | |
| Bohling et al. | Comparison of clot-based vs chromogenic factor Xa procoagulant phospholipid activity assays | |
| JP5963984B2 (ja) | 甲状腺刺激抗体測定における試料の前処理方法 |